Last Updated on December 25, 2024 by The Health Master
Nutraceuticals
The Karnataka High Court has provided a temporary reprieve to the pharmaceutical industry, specifically those pharma units involved in the manufacturing of nutraceuticals.
he court has issued an order directing the government to refrain from taking any action against pharma units that produce nutraceuticals within facilities licensed for drug production.
This decision comes in response to a legal challenge filed by the Federation of Pharma Enterprises (FoPE) and other industry associations against the newly notified Schedule M.
What is Schedule M?
Schedule M, a set of regulations, proposes a strict prohibition on the manufacturing of any product other than drugs within a drug manufacturing facility.
This blanket ban has raised concerns within the pharmaceutical industry, particularly for manufacturers of nutraceuticals.
Industry Concerns
The industry associations argued that the implementation of Schedule M would pose significant financial burdens.
Setting up entirely separate plants exclusively for cosmetic manufacturing is deemed economically unviable for many medium and small-scale pharmaceutical units.
A Compromise Solution
The industry representatives proposed a compromise solution.
They requested that drug manufacturing facilities be allowed to produce nutraceuticals within designated areas specifically dedicated to the manufacturing of topical products, such as creams and lotions.
The Court’s Stance
The court acknowledged the industry’s concerns and recognized the potential for the government to take immediate action against pharma units manufacturing nutraceuticals within their existing facilities.
To prevent such actions while the matter is under consideration, the court issued an order prohibiting the government from taking any “precipitative action” against the petitioners.
Background
This court order follows an earlier directive from the government that threatened action against pharma units found to be violating regulations by manufacturing nutraceuticals, health supplements, and drugs within the same facility.
Key Takeaways:
- The Karnataka High Court has temporarily halted government action against pharma units manufacturing nutraceuticals within drug manufacturing facilities.
- This decision provides crucial relief to the pharmaceutical industry, which had expressed concerns about the economic impact of Schedule M.
- The court will continue to examine the matter and determine the appropriate course of action for the manufacturing of nutraceuticals.
-
What are nutraceuticals?
Nutraceuticals are products derived from food sources that provide health benefits beyond basic nutrition. They can include vitamins, minerals, herbs, and other natural substances.
-
What is the significance of Schedule M?
Schedule M aims to enhance the quality and safety of pharmaceutical products by ensuring strict manufacturing standards. However, the industry argues that the blanket ban on co-manufacturing could hinder innovation and increase production costs.
-
What is the next step in this legal process?
The court will continue to hear arguments from both sides and ultimately decide on the validity and scope of Schedule M.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Note: This article is for informational purposes only and does not constitute legal advice.
The Future of Health Supplements: New Stricter Regulations
Recommendations for New Rules for Nutraceuticals: FSSAI
CDSCO to implement stricter regulations for health supplements
Nutraceutical Industry seeks separate Regulatory Agency
Govt Considers Price Control on Nutraceuticals in India
Nutraceutical Manufacturing in Drug Facilities: 5 members committee formed
India emerges as a Global Nutraceutical Powerhouse
Nutraceuticals in Drug Units: Panel to examine the issue
FOPE: Impact of revised Schedule M on Pharma and Nutraceuticals
Exploring Regulatory Shifts: Nutraceuticals and the Role of CDSCO
Indian Pharma Industry’s journey into Nutraceuticals
Nutraceuticals in India: A step towards empowering Pharma Industry
Nutraceutical Industry: Opportunities and Measures for India
Nutraceutical industry trends will rule the year
IPA calls Nutraceutical, Pharma industries to join hands to provide holistic care
Nutraceuticals Regulations 2022 to encourage Pharma Industry
Nutraceuticals: India can become a Global Leader
Nutraceuticals: A strong Regulation is needed
Bring Nutraceuticals for prevention of diseases under DCGI’s regulation: Experts to Govt
Nutraceuticals for mental well-being
Nutraceuticals: From Alternative to Mainstream
Nutraceuticals in India: A game changing opportunity
Indian Nutraceutical industry now a days
Nutraceutical Industry: A trending Market
PLI scheme: Boost for the growth of the Nutraceutical sector
Recommendations for New Rules for Nutraceuticals: FSSAI
Nutraceutical Industry seeks separate Regulatory Agency
Govt Considers Price Control on Nutraceuticals in India
Telangana DCA Uncover Illegally Manufactured “Nutraceuticals”
Nutraceutical Manufacturing in Drug Facilities: 5 members committee formed
NPPA fixed retail price of 7 formulations: December 2024
Revised Schedule M: Industry seeks balance between Quality and Viability
FDA Karnataka enters a New Era of Food and Drug Safety
Key Notes on Revised Schedule M: Point No. 13 – Equipment
GST Penalty of Rs. 1.11 Crore on Cipla
FSSAI regulations on use of Methylcobalamin in Supplements
FOPE demands inclusion of Sensitive drugs in Schedule P
Parliamentary Panel demands swift action on Spurious Drugs
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
